Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting

By afschroeder • December 5, 2025

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein DA, Sobrin L, Kim IK, Singh K, Chambers WA, Boyd WM, Silverstein J, Pohlmann PR, Lu J, Glencer AC, Huppert LA, Chien AJ, Rugo HS, Esserman LJ. Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting. JAMA Ophthalmol. 2025 Dec 4. doi: 10.1001/jamaophthalmol.2025.3159. Epub ahead of print. PMID: 41343206.

Tags: Fellow, Hematology/Oncology, Publications

Related Posts

The evolving role of ctDNA in colorectal cancer: guidance of adjuvant therapy or surveillance strategies?

Barrett LG, Gangi A, Hendifar A, Osipov A, Atkins K, Zaghiyan K, Nasseri Y, Murrell Z, Waters K, Mehta P, Zell JA, Hitchins MP, Gong[...]

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin[...]